Biocon Names New CEO to Steer Unified Biopharma Powerhouse 

Key Highlights: 

• Biocon has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026, following board approval. As the first CEO of the integrated entity, he will lead the combined biosimilars and generics platform to strengthen global scale and competitiveness 

• The leadership transition follows the integration of Biocon Biologics as a wholly owned subsidiary, creating a unified corporate structure. The combined entity will focus on key therapy areas including diabetes, obesity, oncology, and immunology, supported by a portfolio spanning biosimilars, insulins, complex generics, peptides, and GLP-1 therapies 

• Tambe, who previously led key milestones such as the Viatris biosimilars for business integration, succeeds Siddharth Mittal, who will transition to another role within the group. With Biocon Biologics already among the top global biosimilar players, the company aims to drive sustained growth and expand access to affordable therapies worldwide 

Implications: 

Biocon is consolidating leadership under Shreehas Tambe to drive its newly integrated biosimilars–generics platform, with a clear focus on scale, portfolio depth, and global competitiveness. 

This transition formally aligns the fully integrated Biocon Biologics and generics businesses under one CEO, allowing Biocon to pursue unified growth in diabetes, obesity, oncology, and immunology using a combined basket of biosimilars, insulins, complex generics, peptides, and GLP‑1 therapies. 
Tambe’s elevation, after leading the Viatris biosimilars acquisition and integration and building Biocon Biologics into a top‑five global biosimilar player, signals continuity on execution while Siddharth Mittal’s move to another group role preserves senior experience within the wider Biocon ecosystem.  

Source: Express Pharma | Image: Biocon Pharma